// Suboxone Help

Archive for December, 2009

Interactions between Buprenorphine and Antiretrovirals: Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) Didanosine, Lamivudine, and Tenofovir.

We report the results of a study designed to examine the interaction between buprenorphine and the nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine (ddI), lamivudine (3TC), and tenofovir (TDF). Opioid-dependent, buprenorphine/naloxone-maintained, HIV-negative volunteers (n = 27) participated in two 24-hour sessions to determine (1) pharmacokinetics of buprenorphine alone and (2) pharmacokinetics of both buprenorphine and either ddI, 3TC, or TDF. Among buprenorphine/naloxone-maintained study participants, no significant changes in buprenorphine pharmacokinetics were observed following ddI, 3TC, or TDF administration. Buprenorphine had no significant effect on NRTI concentrations. Concomitant use of buprenorphine with ddI, 3TC, or TDF results in neither a significant pharmaco…

Interactions between Buprenorphine and Antiretrovirals: Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) Didanosine, Lamivudine, and Tenofovir.

We report the results of a study designed to examine the interaction between buprenorphine and the nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine (ddI), lamivudine (3TC), and tenofovir (TDF). Opioid-dependent, buprenorphine/naloxone-maintained, HIV-negative volunteers (n = 27) participated in two 24-hour sessions to determine (1) pharmacokinetics of buprenorphine alone and (2) pharmacokinetics of both buprenorphine and either ddI, 3TC, or TDF. Among buprenorphine/naloxone-maintained study participants, no significant changes in buprenorphine pharmacokinetics were observed following ddI, 3TC, or TDF administration. Buprenorphine had no significant effect on NRTI concentrations. Concomitant use of buprenorphine with ddI, 3TC, or TDF results in neither a significant pharmaco…

Lack of Clinically Significant Drug Interactions between Nevirapine and Buprenorphine.

This study was conducted to determine whether drug interactions of clinical importance occur between buprenorphine, an opioid partial agonist medication used in treatment of opioid dependence, and the nonnucleoside reverse transcriptase inhibitor (NNRTI) nevirapine. Opioid-dependent, buprenorphine/naloxone-maintained, HIV-negative volunteers (n = 7) participated in 24-hour sessions to determine the pharmacokinetics of buprenorphine alone and of buprenorphine and nevirapine following administration of 200 mg nevirapine daily for 15 days. Opiate withdrawal symptoms, cognitive effects, and adverse events were determined prior to and following nevirapine administration. Modest decreases were observed for AUC for buprenorphine and its metabolites. There was a trend for more rapid clearance of b…

Effect of cocaine use on buprenorphine pharmacokinetics in humans.

Authors: McCance-Katz EF, Rainey PM, Moody DE The effect of chronic cocaine use on buprenorphine pharmacokinetics was investigated to identify drug interactions and potential toxicities. In a retrospective analysis, pharmacokinetics were compared for 16 studies completed on subjects who were regular cocaine users and 74 studies on subjects who used cocaine only occasionally or not at all. All participants were stably maintained on buprenorphine/naloxone 16/4 mg daily. Participants who used cocaine regularly had lower buprenorphine exposure (AUC 34% lower; C(max) 27% lower and C(24) 37% lower; p </= .001 for all comparisons). Regular cocaine users were younger (p = .0007), and used more heroin (p = .004) and cocaine (p < .0001). Regular cocaine use may result in lower buprenorphin…

Effect of cocaine use on buprenorphine pharmacokinetics in humans.

Authors: McCance-Katz EF, Rainey PM, Moody DE The effect of chronic cocaine use on buprenorphine pharmacokinetics was investigated to identify drug interactions and potential toxicities. In a retrospective analysis, pharmacokinetics were compared for 16 studies completed on subjects who were regular cocaine users and 74 studies on subjects who used cocaine only occasionally or not at all. All participants were stably maintained on buprenorphine/naloxone 16/4 mg daily. Participants who used cocaine regularly had lower buprenorphine exposure (AUC 34% lower; C(max) 27% lower and C(24) 37% lower; p </= .001 for all comparisons). Regular cocaine users were younger (p = .0007), and used more heroin (p = .004) and cocaine (p < .0001). Regular cocaine use may result in lower buprenorphin…

The Association between Cocaine Use and Treatment Outcomes in Patients Receiving Office-Based Buprenorphine/Naloxone for the Treatment of Opioid Dependence.

Authors: Sullivan LE, Moore BA, O’Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA Cocaine use in patients receiving methadone is associated with worse treatment outcomes. The association between cocaine use and office-based buprenorphine/naloxone treatment outcomes is not known. We evaluated the association between baseline and in-treatment cocaine use, treatment retention, and urine toxicology results in 162 patients enrolled in a 24-week trial of primary care office-based buprenorphine/naloxone maintenance. Patients with baseline cocaine metabolite-negative urine toxicology tests compared with those with cocaine metabolite-positive tests had more mean weeks of treatment retention (18.3 vs. 15.8, p = .04), a greater percentage completed 24 weeks of treatment (50% vs. 33…

The Association between Cocaine Use and Treatment Outcomes in Patients Receiving Office-Based Buprenorphine/Naloxone for the Treatment of Opioid Dependence.

Authors: Sullivan LE, Moore BA, O’Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA Cocaine use in patients receiving methadone is associated with worse treatment outcomes. The association between cocaine use and office-based buprenorphine/naloxone treatment outcomes is not known. We evaluated the association between baseline and in-treatment cocaine use, treatment retention, and urine toxicology results in 162 patients enrolled in a 24-week trial of primary care office-based buprenorphine/naloxone maintenance. Patients with baseline cocaine metabolite-negative urine toxicology tests compared with those with cocaine metabolite-positive tests had more mean weeks of treatment retention (18.3 vs. 15.8, p = .04), a greater percentage completed 24 weeks of treatment (50% vs. 33…MedWorm Sponsor Message: Watch the new MedWorm demo and find out how to get all the very latest, relevant, organized information daily!

Are you ANXIOUS? Are you SURE?

I’ve been posting more lately, but I’m hoping to slow down by the end of the holidays to let everyone catch up. I’ve also mentioned ‘my book’ several times in the past year, promising to myself and to others deadline that comes and go. I wish I could take a month and work on it full-time, [...]

Steve Tyler: Another one of us opiate addicts who isn’t cured yet!

Had to mention that I heard that Steve Tyler went in for rehab for ‘pain pill addiction’ related to falling off a stage or some other injury… Wish I had that ‘falling off the stage’ line when Men’s Health did their story about me!
I keep thinking that wil all the young people dying from overdoses [...]

Brittany Murphy’s medications and their interactions

A note of follow up: According to TMZ, a variety of medications were found in Brittany Murphy’s apartment under her name and under the name of her husband and mother. Of course it is possible that the medications actually belonged to her husband and to her mother– but as you read in my last post, I [...]

Contact Us

Your Name (required)

Your Email (required)

Your Phone # (optional)

Subject

Enter the text from the image below:
captcha

Your Message

Sorry for the quiz, but we're getting a lot of spam!
1+1=? 

Suboxone Articles

Capsule Yellow R Phentermine Mutual 274
February 20, 2011
By Suboxone Helpline Web Team
ethex generic 80mg oxycontin
February 20, 2011
By Suboxone Helpline Web Team
clonidine use in oxycotin detox
February 20, 2011
By Suboxone Helpline Web Team